SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : RNAi
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (593)9/3/2008 2:29:38 PM
From: Ian@SI   of 671
 
Clearly, getting off target immune responses would almost certainly be undesirable most, if not all, of the time.

After reflecting further about the PR, would the pt or Dr care, if an on target response cured the disease whether or not it was a direct result of the siRNA or the result of an immune reaction to that siRNA? Seems to me a successful tx is more than acceptable regardless of the precise pathway to that cure.

And a cure via an Immune response could well be more lasting.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News